QQ客服 官方微博 反馈留言

	A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer
	Zhang, Yan; Zhang, Qianwen; Chen, Yaqing; Qian, Jianchang; Zhang, Xuesai; Yu, Ker
刊名	CLINICAL CANCER RESEARCH
	2019
卷号	25期号:12
ISSN号	1078-0432
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3594542
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Zhang, Yan,Zhang, Qianwen,Chen, Yaqing,et al. A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer[J]. CLINICAL CANCER RESEARCH,2019,25(12).
APA	Zhang, Yan,Zhang, Qianwen,Chen, Yaqing,Qian, Jianchang,Zhang, Xuesai,&Yu, Ker.(2019).A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.CLINICAL CANCER RESEARCH,25(12).
MLA	Zhang, Yan,et al."A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer".CLINICAL CANCER RESEARCH 25.12(2019).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。